|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Obesity and colorectal cancer:Role of adipokines in tumor initiation and progression显示文摘Obesity-associated diseases account for a large portion of public health challenges.Among obesity-related disorders,a direct and independent relationship has been ascertained for colorectal cancer(CRC).The evidence that adipocyte hypertrophy and excessive adipose tissue accumulation(mainly visceral)can promote pathogenic adipocyte and adipose tissue-related diseases,has led to formulate the concept of'adiposopathy',defined as adipocyte and adipose tissue dysfunction that contributes to metabolic syndrome.Adipose tissue can,indeed,be regarded as an important and highly active player of the innate immune response,in which cytokine/adipokine secretion is responsible for a paracrine loop between adipocytes and macrophages,thus contributing to the systemic chronic low-grade inflammation associated with visceral obesity,which represents a favorable niche for tumor development.The adipocyte itself participates as a central mediator of this inflammatory response in obese individuals by secreting hormones,growth factors and proinflammatory cytokines,which are of particular relevance for the pathogenesis of CRC.Among adipocyte-secreted hormones,the most relevant to colorectal tumorigenesis are adiponectin,leptin,resistin and ghrelin.All these molecules have been involved in cell growth and proliferation,as well as tumor angiogenesis and it has been demonstrated that their expression changes from normal colonic mucosa to adenoma and adenocarcinoma,suggesting their involvement in multistep colorectal carcinogenesis.These findings have led to the hypothesis that an unfavorable adipokine profile,with a reduction of those with an anti-inflammatory and anti-cancerous activity,might serve as a prognostic factor in CRC patients and that adipokines or their analogues/antagonists might become useful agents in the management or chemoprevention of CRC. | Silvia Riondino Mario Roselli Raffaele Palmirotta David Della-Morte Patrizia Ferroni Fiorella Guadagni | 2014 | World Journal of Gastroenterology2014，20，18： | 20 |
| 2 | Targeted therapy in first line treatment of RAS wild type colorectal cancer显示文摘The debate on the optimal drug combination for treating chemotherapy-nave patients with metastatic colorectal cancer has recently become particularly heated.The present editorial will review recent data on this topic.The FIRE-3 and PEAK trials have shown a 7.5 to 12 mo survival advantage with the use anti-epidermal growth factor receptor(anti-EGFR)antibodies.The CALGB 80405 has shown no difference between anti-EGFR and anti-vascular endothelial growth factor agents.All three trials have consistently shown a significant increase in objective response rate.These data suggest that there is a subset of metastatic colorectal cancer patients,rigorously selected by molecular profiling,who particularly benefit from an anti-EGFR-based regimen in the first-line setting. | Vincenzo Formica Mario Roselli | 2015 | World Journal of Gastroenterology2015，21，10： | 6 |
| 3 | Immune reaction and colorectal cancer:Friends or foes?显示文摘The potential clinical impact of enhancing antitumor immunity is increasingly recognized in oncology therapeutics for solid tumors.Colorectal cancer is one of the most studied neoplasms for the tumor-host immunity relationship.Although immune cell populations involved in such a relationship and their prognostic role in colorectal cancer development have clearly been identified,still no approved therapies based on host immunity intensification have so far been introduced in clinical practice.Moreover,a recognized risk in enhancing immune reaction for colitis-associated colorectal cancer development has limited the emphasis of this approach.The aim of the present review is to discuss immune components involved in the host immune reaction against colorectal cancer and analyze the fine balance between pro-tumoral and anti-tumoral effect of immunity in this model of disease. | Vincenzo Formica Vittore Cereda Antonella Nardecchia Manfredi Tesauro Mario Roselli | 2014 | World Journal of Gastroenterology2014，20，35： | 3 |
| 4 | Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B)显示文摘 | Vincenzo Formica Vittore Cereda Maria-Giovana Bari Italia Grenga Manfredi Tesauro Palmirotta Raffaele Patrizia Ferroni Fiorella Guadagni Mario Roselli | 2013 | Medical Oncology2013，，4： | 2 |
| 5 | Novel High-Sensitive D-Dimer Determination Predicts Chemotherapy-Associated Venous Thromboembolism in Intermediate Risk Lung Cancer Patients显示文摘 | Patrizia Ferroni Francesca Martini Ilaria Portarena Gioia Massimiani Silvia Riondino Francesca La Farina Sabrina Mariotti Fiorella Guadagni Mario Roselli | 2012 | Clinical Lung Cancer2012，，6： | 1 |
| 6 | Risk Factors and Prognostic Indicators of Bacterial Meningitis in a Cohort of 3580 Postneurosurgical Patients显示文摘 | Giovanni Federico Mario Tumbarello Teresa Spanu Romeo Roselli Maurizio Iacoangeli Massimo Scerrati Evelina Tacconelli | 2001 | Scandinavian Journal of Infectious Diseases2001，，7： | 1 |
| 7 | Novel High-Sensitive D-Dimer Determination Predicts Chemotherapy-Associated Venous Thromboembolism in Intermediate Risk Lung Cancer Patients显示文摘 | Patrizia Ferroni Francesca Martini Ilaria Portarena Gioia Massimiani Silvia Riondino Francesca La Farina Sabrina Mariotti Fiorella Guadagni Mario Roselli | 2012 | Clinical Lung Cancer2012，，6： | 1 |
| 8 | Clinical significance of glycemic parameters on venous thromboembolism risk prediction in gastrointestinal cancer显示文摘AIM To investigate the possible predictive role of routinely used glycemic parameters for a first venous thromboembolism(VTE) episode in gastrointestinal(GI) cancer ambulatory patients-with or without clinically diagnosed type 2 diabetes(T2D) or obesity-treated with chemotherapy.METHODS Pre-treatment fasting blood glucose,insulin,glycated hemoglobin(Hb A1c) and homeostasis model of risk assessment(HOMA) were retrospectively evaluated in a cohort study of 342 GI cancer patients. Surgery was performed in 142(42%) patients with primary cancer,30(21%) and 112(79%) of whom received neoadjuvant and adjuvant therapies,respectively. Firstline chemotherapy was administered in 200(58%) patients with metastatic disease. The study outcome was defined as the occurrence of a first symptomatic or asymptomatic VTE episode during active treatment.RESULTS Impaired glucose tolerance(IGT) or T2 D were diagnosed in 30% of GI cancer patients,while overweight/obesity had an incidence of 41%. VTE occurred in 9.4% of patients(7% of non-diabetic non-obese),especially in those with a high ECOG score(P = 0.025). No significant association was found between VTE incidence and T2 D,obesity,different tumor types,metastatic disease,Khorana class of risk,or different anti-cancer drugs,although VTE rates were substantially higher in patients receiving bevacizumab(17% vs 8%,P = 0.044). Conversely,all glucose metabolic indexes were associated with increased VTE risk at ROC analysis. Multivariate Cox proportional analyses confirmed that HOMA index(HR = 4.13,95%CI: 1.63-10.5) or fasting blood glucose(HR = 3.56,95%CI: 1.51-8.39) were independent predictors of VTE occurrence during chemotherapy.CONCLUSION The results here reported demonstrate that evaluating glucose metabolic asset may allow for VTE risk stratification in GI cancer,helping to identify chemotherapy-treated patients who might benefit from thromboprophylaxis. Further multicenter prospective studies involving a larger number of patients are presently needed. | Fiorella Guadagni Silvia Riondino Vincenzo Formica Girolamo Del Monte Anna Maria Morelli Jessica Lucchetti Antonella Spila Roberta D’Alessandro David Della-Morte Patrizia Ferroni Mario Roselli | 2017 | World Journal of Gastroenterology2017，23，28： | 1 |
| 9 | Biologic evaluation of tumor-associated glycoprotein-72 and carcinoembryonic antigen expression in colorectal cancer, part I显示文摘 | Dr. Fiorella Guadagni M.D. Mario Roselli M.D. Maurizio Cosimelli M.D. Antonella Spila Ph.D. Francesco Cavaliere M.D. Raffaella Arcuri M.D. Maria Rosaria Abbolito Ph.D. John W. Greiner Ph.D. Jeffrey Schlom Ph.D | 1994 | Diseases of the Colon & Rectum1994，，2： | 1 |
| 10 | Prognostic value of glycated hemoglobin in colorectal cancer显示文摘AIM To investigate the clinical significance of routinely used glycemic parameters in a cohort of colorectal cancer(CRC) patients.METHODS Pre-treatment fasting blood glucose, insulin, Hb A1 c and homeostasis model of risk assessment(HOMA-IR) were retrospectively evaluated in a case-control study of 224 CRC and 112 control subjects matched for sex, obesity and diabetes frequency and blood lipid profile.Furthermore, the prognostic value of routinely used glycemic parameters towards progression-free(PFS) and overall survival(OS) was prospectively evaluated.RESULTS Fasting blood glucose, insulin, HOMA-IR and HbA 1c(all P < 0.0001) levels were higher in non-diabetic CRC patients compared with obesity-matched controls. All parameters were associated with increased CRC risk at ROC analysis, but no relationship with clinical-pathological variables or survival outcomes was observed for glycemia, insulinemia or HOMA-IR. Conversely, advanced CRC stage(P = 0.018) was an independent predictor of increased Hb A1 c levels, which were also higher in patients who had disease progression compared with those who did not(P = 0.05). Elevated Hb A1 c levels showed a negative prognostic value both in terms of PFS(HR = 1.24) and OS(HR = 1.36) after adjustment for major confounders, which was further confirmed in a subgroup analysis performed after exclusion of diabetic patients.CONCLUSION HbA 1c might have a negative prognostic value in CRC, thus suggesting that glycemic metabolic markers should be carefully monitored in these patients, independently of overt diabetes. | Patrizia Ferroni Vincenzo Formica David Della-Morte Jessica Lucchetti Antonella Spila Roberta D'Alessandro Silvia Riondino Fiorella Guadagni Mario Roselli | 2016 | World Journal of Gastroenterology2016，22，45： | 0 |
| 11 | Artificial intelligence for the study of colorectal cancer tissue slides显示文摘Artificial intelligence(AI)is gaining incredible momentum as a companion diagnostic in a number of fields in oncology.In the present mini-review,we summarize the main uses and findings of AI applied to the analysis of digital histopathological images of slides from colorectal cancer(CRC)patients.Machine learning tools have been developed to automatically and objectively recognize specific CRC subtypes,such as those with microsatellite instability and high lymphocyte infiltration that would optimally respond to specific therapies.Also,AI-based classification in distinct prognostic groups with no studies of the basic biological features of the tumor have been attempted in a methodological approach that we called“biology-agnostic”. | Vincenzo Formica Cristina Morelli Silvia Riondino Nicola Renzi Daniele Nitti Mario Roselli | 2020 | Artificial Intelligence in Gastroenterology2020，1，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员